Clinical Trials Network - Network Organization

Skip Navigation

NIDA NEWS

The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse

Search the NIDA website

Osmotic-Release Methylphenidate (OROS MPH) for ADHD in Adolescents with Substance Use Disorders (CTN 0028)

Enrollment (Closed)

Description

The primary objectives of this study are to evaluate the efficacy of OROS-MPH (Concerta), relative to placebo, in treating ADHD and decreasing substance use in adolescents with ADHD and a substance use disorder (SUD). The study will involve approximately 300 participants, recruited from 10 community treatment sites.

For further information on clinical trials, click here.

Available Brochures

Should I join ?	.PDF	.HTML
Patient Brochure	.PDF	.HTML

You need Adobe Acrobat Reader in order to view the .pdf file.
Acrobat Reader can be downloaded for free from www.adobe.com.

Principal Investigator :

Paula Riggs, M.D.
E-Mail : paula.riggs@uchsc.edu
Phone : (303) 315-7652

NODES & CTPs:

Ohio Valley Node (Lead)
Crittenton
Synergy Treatment Center

Appalachian Tri-State Node
Addiction Medicine Services (WPIC)

Delaware Valley Node
Rehab After Work-Life Counseling Services

Florida Node
Gateway Community Services
Operation PAR, Inc.

Long Island Node
St. Luke's Roosevelt Hospital Center

Mid-Atlantic Node
Mountain Manor Treatment Programs

Northern New England Node
SSTAR of Massachusetts
SSTAR of Rhode Island

Southern Consortium Node
Lexington - Richland Alcohol and Drug Council

Texas Node
Mental Health and Mental Retardation of Tarrant County

The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Thursday, June 26, 2008.